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Objective: Implantation of a left ventricular assist device as a bridge to transplan-
tation has become an acceptable approach for patients with end-stage heart failure.
Our long-term results with 3 Thoratec HeartMate devices are presented to outline
improvements in successful bridging to transplantation and post-transplant survival.
Methods: From August 1990 through January 2003, 243 patients underwent im-
plantation of Thoratec HeartMate devices as a bridge to transplantation. This
included 52 (21.4%) pneumatic devices, 17 (7.0%) dual-lead vented electric de-
vices, and 174 (71.6%) single-lead vented electric devices.
Results: Mean age was 49.7 13.7 years. Mean support time was 78.1 82.9 days
(0-541). Bridging success increased from 63.5% (n  33) for pneumatic devices to
64.7% (n  11) for dual-lead vented electric devices and 72.4% (n  126) for
single-lead vented electric devices (P  .005). Posttransplant 1-, 3-, and 5-year
actuarial survival increased from 87.5%, 78.1%, and 71.9% in patients with pneu-
matic devices to 91.5%, 86.9%, and 81.3%, respectively, for patients with single-
lead vented electric devices. Device infection and malfunction occurred in 17.7% (n
 43) and 12.8% (n  31) of patients, respectively.
Conclusions: Successful bridging to transplantation and posttransplant survival has
improved over time. Left ventricular assist devices have become increasingly more
effective in bridging patients with end-stage heart failure to transplantation. This is
likely due to a combination of better patient selection, improvements in clinical
practice, and evolution in device design.
Cardiac failure remains the leading cause of death in the UnitedStates, affecting more than 5 million individuals with approxi-mately 400,000 new cases diagnosed each year.1,2 Implantation ofa left ventricular assist device (LVAD) as a bridge to transplanta-tion has become an acceptable approach for patients with end-stageheart failure.3-6 Potential complications, however, include bleed-
ing, right heart failure, stroke, device-related infections, and device malfunction.7,8
Over the last 12 years, the HeartMate (Themocardiosystems, Woburn, Mass) has
been the preferred device at our institution for bridging patients with end-stage heart
failure to transplantation and has been used with the greatest frequency.9-12 With
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this device, patients can be stabilized and discharged from
the hospital to wait for their heart transplant at home.13-15
Early survival data of patients undergoing LVAD inser-
tion revealed greater than 30% hospital mortality. Since the
initiation of our LVAD program in 1990, there have been
many clinical improvements in perioperative care.9 We
reviewed our 12-year experience with 3 different HeartMate
devices, focusing on the temporal changes in duration of
support, bridge to transplant success, and posttransplant
survival. Additionally, we evaluated the incidence of the
most common device-related complications, including in-
fection, device malfunction, and stroke, as well as causes of
death for those patients who expired on LVAD support.
Finally, we outlined preoperative, intraoperative, and post-
operative improvements in care as well as advancements in
device design that have favorably impacted the success of
LVADs in bridging patients to transplantation.
We challenged ourselves to answer the following ques-
tions: Has bridging success to transplantation improved
over the years as device design and clinical practices have
evolved? What were the primary advancements in preoper-
ative, intraoperative, and postoperative care that may have
been responsible for improved bridging to transplant suc-
cess? Finally, was our recently reported LVAD screening
scale accurate in its ability to predict survival to transplant?
Patients and Methods
From August 1990 through January 2003, 243 patients underwent
implantation of a Thoratec HeartMate device. This included 52
(21.4%) pneumatic (PNEUM), 17 (7.0%) dual-lead vented electric
(DLVE), and 174 (71.6%) single-lead vented electric (SLVE)
devices. Data were collected prospectively and analyzed retrospec-
tively. Initial approval for device placement was obtained from the
institutional review board and informed consent was obtained from
each patient.
Duration of support, bridging to transplant success, survival
posttransplant, incidence of infection, and device malfunction
were evaluated based on type of device and time period. Infection
was defined as the presence of a positive culture along with a
leukocytosis. Device malfunction was categorized into electrical,
mechanical, and technical causes.
We previously reported a preoperative scoring system that predicts
successful bridging to transplant.16 LVAD implantation scores, de-
rived from 5 clinical variables, including ventilatory dependence,
postcardiotomy shock, previous LVAD, central venous pressure16
mm Hg, and prothrombin time 16 seconds, were calculated for
patients with SLVE devices.16 LVAD scores were classified as low
(0-4), medium (5-7), and high (8-10), with an inverse relationship
between score and clinical stability. Mean LVAD score during
each year was calculated and all years were compared.
Statistical Analysis
Data were represented as frequency distributions and simple per-
centages. Values of continuous variables were expressed as a mean
 standard deviation (SD). Continuous variables were compared
using analysis of variance (ANOVA-Bonferroni), whereas cate-
gorical variables were compared by means of chi-square tests.
Kaplan-Meier analysis was used to calculate long-term survival
along with a log-rank P value when comparing groups. Actuarial
survival was calculated by constructing life tables. Significant
predictors of bridging to transplant success were investigated by
examining the association between various preoperative variables
and bridging success in univariate analysis, followed by a stepwise
logistic regression analysis on factors demonstrated to be signifi-
cant in univariate analysis. Variables included age, sex, race,
etiology of heart failure, development of infection, device mal-
function, and LVAD implantation scores. All data were analyzed
utilizing SPSS 11.5 (SPSS Inc, Chicago, Ill).
Results
Demographics
Table 1 outlines the clinical characteristics of LVAD recip-
ients. Mean overall age was 49.7  13.7 years, with 197
(81.1%) men and 46 (18.9%) women. Coronary artery dis-
ease (CAD) was the most common etiology of heart failure,
present in 138 (56.8%) patients. Idiopathic cardiomyopathy
(ICM) was the second most common etiology, identified in
87 (35.8%) patients. Other etiologies occurred in 18 (7.4%)
patients and included postpartum cardiomyopathy (CM) (n
 2, 0.8%), hypertrophic CM (n 4, 1.6%), amyloidosis (n
 3, 1.2%), and myocarditis (n  9, 3.7%).
Overall mechanical support time was 78.1  82.9 (0-
541) days. Mean support time significantly decreased from
a mean of 99.0  91.8 days for PNEUM devices to 65.3 
66.2 days for SLVE devices (P  .001).
Bridging to Transplant Success
Bridging to transplant success significantly increased from
63.5% (n 33) for PNEUM devices to 72.4% (n 126) for
SLVE devices (P  .005; Figure 1). Causes of death for
patients who expired on LVAD support are listed in Table 2.
Posttransplant Survival
Overall actuarial survival at 1, 3, 5, and 10 years posttrans-
plant was 90.5%, 85.1%, 69.6%, and 39.6%, respectively
(Figure 2). Posttransplant 1-, 3-, and 5-year actuarial sur-
vival increased from 87.5%, 78.1%, and 71.9% for PNEUM
devices to 91.5%, 86.9%, and 81.3%, respectively, for
SLVE devices. Posttransplant survival was similar for pa-
tients who were bridged to transplant with an LVAD as
compared to nonbridged patients operated on during the
same time period at our institution (P  NS; Figure 2).
Explantation of Devices
Over the 12-year study period, 10 devices were explanted.
This included 2 PNEUM devices, 3 DLVE devices, and 5
SLVE devices. Seven of 10 devices were explanted because
of infection, whereas 3 were explanted because of left
ventricular recovery in patients with myocarditis, idiopathic
cardiomyopathy, and acute myocardial infarction with ven-
tricular rupture (all patients with SLVE devices).
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Infection and Device Malfunction
The overall incidence of infection was 17.7% (n  43),
occurring in 25.0% (n  13) of patients with PNEUM
devices, 0.0% (n  0) of patients with DLVE devices, and
17.2% (n  30) of patients with SLVE devices (Table 1).
Device malfunctions occurred in 15.4% (n 8) of PNEUM
devices, 29.4% (n  5) of DLVE devices, and 10.3% (n 
18) of SLVE devices (Table 3). When considering only
those device malfunctions that were clinically significant
(excluding incidental findings at explantation), the inci-
dence was 11.5% (n  6) in PNEUM devices, 23.5% (n 
4) in DLVE devices, and 5.7% (n  10) in SLVE devices
(Table 3).
Neurological Complications While on LVAD Support
The incidence of postoperative cerebrovascular accident
(CVA) and transient ischemic attack (TIA) is outlined in
Table 4. Postoperative stroke (within 30 days of LVAD
implantation) occurred in 7.7% (n  4) of patients with
PNEUM devices, 11.8% (n  2) of patients with DLVE
devices, and 4.0% (n 7) of patients with SLVE devices (P
 .443).
Severe Right Ventricular Failure While on LVAD
Support
The incidence of severe right ventricular failure requiring
placement of a right ventricular assist device (RVAD) oc-
curred in 5 (29.4%) patients with DLVE devices and 12
(6.9%) patients with SLVE devices. Bridging to transplant
was successful in 11 (64.7%) of these patients supported by
an RVAD.
LVAD Score
LVAD implantation scores increased from 2.6  3.1 in
1996, to 3.8  3.3 in 1997, to 4.9  3.6 in 1998, to 5.3 
3.5 in 1999, and to 5.4 3.8 in 2000. Scores then decreased
to 5.3  3.3 in 2001 and 4.7  3.4 in 2002 (P  .297).
Predictors of Survival
Univariate analysis. Table 5 outlines numerous vari-
ables that were evaluated for their impact on bridging to
transplant success using univariate analysis. Significant risk
factors adversely affecting survival included female gender
(P  .001), etiology of heart failure (CAD: P  .044; ICM:
P  .003; other: P  .048), duration of LVAD support (P
 .001), and LVAD score (P  .001). Additionally, there
was a trend toward significance for advanced age (P .080)
and pocket infections (P  .095).
Multivariate analysis. Only LVAD score (odds ratio
1.214, 95% confidence interval 1.119-1.316, P  .001,
standard error 0.041) was a significant predictor of survival
to transplant using multivariate, stepwise logistic regression
analysis (Table 6). Bridging to transplant was successful in
88.6% of low-scoring patients, 64.5% of medium-scoring
patients, and 48.9% of high-scoring patients (P  .001;
Figure 3).
TABLE 1. Clinical characteristics of LVAD recipients
PNEUM DLVE SLVE P Overall
Mean age (years) 51.1 11.2* 49.5 16.2 49.2 14.1 .665 49.7 13.7
Gender
Male 40 (76.9%)† 15 (88.2%) 142 (81.6%) .549 197 (81.1%)
Female 12 (23.1%) 2 (11.8%) 32 (18.4%) 46 (18.9%)
Race
Caucasian 42 (80.8%) 15 (88.2%) 129 (74.1%) .317 186 (76.5%)
African American 8 (15.4%) 1 (5.9%) 30 (17.2%) .265 39 (16.0%)
Other 2 (3.8%) 1 (5.9%) 15 (8.6%) .592 18 (7.4%)
Etiology of heart failure
CAD 29 (55.8%) 11 (64.7%) 98 (56.3%) .672 138 (56.8%)
ICM 18 (34.6%) 5 (29.4%) 64 (36.8%) .635 87 (35.8%)
Other 5 (9.6%) 1 (5.9%) 12 (6.9%) .935 18 (7.4%)
Duration of support (days) 99.0 91.8 136.9 145.6 65.3 66.2 .001 78.1 82.9
Range (days) 0–362 11–541 0–397 0–541
Infection
Drive line 6 (11.5%) 0 (0.0%) 12 (6.9%) .299 18 (7.4%)
Pocket 1 (1.9%) 0 (0.0%) 14 (8.0%) .029 15 (6.2%)
Pump 6 (11.5%) 0 (0.0%) 4 (2.3%) .008 10 (4.1%)
Any 13 (25.0%) 0 (0.0%) 30 (17.2%) .036 43 (17.7%)
LVAD, Left ventricular assist device; PNEUM, pneumatic device; DLVE, dual-lead vented electric device; SLVE, single-lead vented electric device; CAD,
coronary artery disease; ICM, idiopathic cardiomyopathy.
*Mean  Standard deviation.
†Absolute number (percentage of total).
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Discussion
LVADs continue to serve as an effective bridge to trans-
plantation for patients with end-stage heart failure. Of the
243 patients who underwent implantation of HeartMate
devices as a bridge to transplantation at our institution over
the last 12 years, 170 (70.0%) were successfully trans-
planted. We are encouraged by our results that demonstrate
a progressive improvement in both bridging to transplant
success and posttransplant survival.
Improvements in bridge to transplant success and post-
transplant survival occurred along with concomitant tempo-
ral changes in device designs. We believe the reasons for
improvement in these outcome variables are multifactorial
and cannot be attributed to changes in device design alone.
Over the last 12 years, there have been numerous improve-
ments in patient selection, surgical techniques, treatments
for right ventricular (RV) dysfunction, establishment of
intraoperative hemostasis, and pre- and postoperative inten-
sive care unit care. As it would be nearly impossible to
quantify the exact contribution of each of these individual
advancements to the progressive improvement in outcome
over the last 12 years, we would like to highlight several of
the preoperative, intraoperative, and postoperative factors
that we believe have most significantly impacted outcome in
patients undergoing implantation of an LVAD as a bridge to
transplant (Table 7).
Improvements in patient selection and medical optimi-
zation prior to LVAD implantation have been the primary
preoperative factors that have contributed to improved out-
come. LVAD implantation score was the only statistically
significant predictor of bridging to transplant success. This
confirmed our belief that patients who are sicker at the time
of LVAD implantation (high LVAD score) exhibit in-
creased mortality during the period of mechanical assistance
and decreased likelihood of being successfully bridged to
transplantation.
Optimizing fluid balance by promoting diuresis with the
use of diuretics and early institution of continuous veno-
venous hemofiltration (CVVH), as well as enhancing renal
perfusion with the use of an intra-aortic balloon pump, can
optimize RV function. Although we currently lack objec-
tive, intrainstitutional data, we believe that optimizing a
patient’s preoperative fluid status decreases the incidence of
postoperative RV dysfunction.
Improvements in intraoperative clinical practices have
centered around 3 areas: RV function after LVAD implan-
tation, decreased bleeding as a result of refined surgical
techniques, and the use of aprotinin, as well as prophylaxis
against infections with topical antibiotic placed around the
preperitoneal LVAD pocket.
LVAD support induces a variety of hemodynamic
changes with resulting effects on RV function.17,18 RV
failure refractory to maximal pharmacological therapy oc-
curs in 20% to 40% of patients supported with an
LVAD.17,18 Though the use of inotropes and vasodilators
may be successful, their effectiveness is limited because
they concomitantly increase the incidence of cardiac ar-
rhythmias, systemic hypotension, and derangement of alve-
olar gas exchange. Early in our experience, we performed a
randomized, double-blind trial of inhaled nitric oxide (NO)
in LVAD recipients with pulmonary hypertension.19 Pa-
tients randomized to receive inhaled NO demonstrated a
significant reduction in pulmonary vascular resistance
(PVR), along with increased LVAD output.19 Patients re-
ceiving placebo did not show a significant response but
demonstrated impressive hemodynamic improvement when
crossed over to the inhaled NO group.19 Prior to the wide-
spread availability of inhaled NO at our institution, 4 of 19
LVAD recipients with RV failure required RVAD support
with an associated mortality of 50%.18 However, more
recently, in an analysis of 69 LVAD recipients, although the
incidence of RV failure was 30%, RV mechanical support
Figure 1. Outcome after insertion of LVAD. Bridging to transplant
success increased from 63.5% (n  33) for patients with PNEUM
devices, to 64.7% (n  11) for patients with DLVE devices, and
72.4% (n  126) for patients with SLVE devices.
TABLE 2. Causes of deaths for patients who died on LVAD
support
Cause of death PNEUM DLVE SLVE P*
MSOF 3 0 13 .378
Sepsis 6 0 8 .267
CVA 2 2 7 .665
Bleeding 3 0 3 .323
Device malfunction 2 1 4 .544
LVAD, Left ventricular assist device; PNEUM, pneumatic device; DLVE,
dual-lead vented electric device; SLVE, single-lead vented electric device;
MSOF, multisystem organ failure; CVA, cerebrovascular accident.
*P values from chi-square analysis.
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was required in only 1 patient.18 Though this study did not
focus on the use of NO, more than half the recipients received
NO perioperatively. More than 65% of patients who received
NO avoided the need for an RVAD. This indicates that the
use of NO may have contributed to the decreased incidence
of RV failure. It is important to note that concomitant
preoperative measures to reduce volume overload (such as
CVVH), avoidance of excessive transfusions, and adminis-
tration of phosphodiesterase inhibitors are also important in
preventing and treating RV failure. Despite overall im-
provements in the management of RV failure, the ability to
consistently predict the development of RV failure in
LVAD recipients is still lacking. This knowledge will be of
greater importance as the use of LVADs for destination
therapy increases.
In our early experience, bleeding was a major limiting
factor in the successful use of an LVAD as a bridge to
transplant. Intraoperative and postoperative requirements
for extensive blood product usage leads to a cytokine-
mediated increase in PVR, with resulting adverse effects on
RV function. We performed a retrospective multicenter
analysis that demonstrated aprotinin to be associated with a
significant decrease in postoperative blood loss and trans-
fusion requirements.20 Additionally, aprotinin recipients
demonstrated an approximate 50% reduction in postopera-
tive requirement for an RVAD, as well as a significant
reduction in mortality.20 We have since used aprotinin rou-
tinely in all patients undergoing LVAD implantation.
Refinements in the operative technique for LVAD im-
plantation have also reduced the degree of postoperative
bleeding. One of the most common sites for bleeding to
occur is at the anastomosis between the left ventricle out-
flow tract and the aorta. In 2001, we modified our surgical
technique for implanting LVADs to evert the suture line to
provide enhanced tissue approximation, as previously de-
scribed.21 BioGlue (Cryolife, Kennesaw, Ga) is then gen-
erously applied over the aortic outflow graft anastomosis.21
Another improvement in intraoperative practice has been
the prophylactic use of vancomycin paste around the pre-
peritoneal pocket during LVAD implantation.22 Since in-
corporating this into our practice a few years ago, we have
noticed a decreased incidence of pocket infections (within
SLVE patients).22
Treatment of vasodilatory hypotension in patients with
vasodilatory shock has also improved over the years with
the usage of arginine vasopressin.23,24 The vasoconstrictive
effect of arginine vasopressin reduces the dependence on
catecholamines, such as dopamine and epinephrine, which
has the potential to increase arrhythmogenicity of myocar-
dial tissue in patients who are already prone to develop
malignant ventricular arrhythmias. An additional benefit of
vasopressin involves its effect on the kidneys. Possibly due
to selective constriction of the efferent arteriole (without
constriction of the afferent arteriole), vasopressin increases
urine output in patients with septic shock.24
Although the development of circulating antibodies,
termed “sensitization,” does not impact early perioperative
LVAD morbidity and mortality, it has significant adverse
long-term effects.25,26 LVAD recipients have prominent
B-cell activation, as evidenced by heightened production of
Figure 2. Posttransplant survival for patients bridged to transplant with a LVAD versus nonbridged patients
operated on during the same time period at our institution. There was no significant difference in posttransplant
survival, with median survival of 8.2 years for LVAD patients and 8.6 years for non-LVAD patients (P  .563).
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anti-human leukocyte antigen class I and II immunoglobulin
G antibodies.26 As a result of these circulating antibodies,
LVAD recipients are subject to repeated positive cross-
matches, increased waiting time to cardiac transplant (with
the risk of increased waiting list mortality), and increased
risk of cellular rejection after transplantation.25 We previ-
ously reported that 66% of Thoratec HeartMate LVAD
recipients at our institution were sensitized.27 Early in our
experience (1992-1996), we noted the development and
subsequent deleterious effects of sensitization in LVAD
recipients. We therefore devised and instituted a treatment
TABLE 3. Device malfunction for different devices
PNEUM DLVE SLVE
Overall incidence 8 (15.4%) 5 (29.4%) 18 (10.3%)
Clinically significant
malfunctions only
6 (11.5%) 4 (23.5%) 10 (5.7%)
Electrical
Faulty display on
console
2
Pump defaulted to
fixed rate
1
Faulty alarming system
Pump stopped,
requiring pneumatic
backup
1 1
Malfunction of
transistor
commutator
1
Software malfunction
Mechanical
Tear in Perc lead 1 1 1
Inflow regurgitation 0 1 2
Inflow regurgitation
noted at
explantation
1
Fractured vent
adapter
1
Technical
Bleeding between
outflow graft and
valve
1 1
Bleeding between
inflow graft and
valve
1
Kinking on inflow graft 1
Other
Hole in inflow graft
near valve
1
Hole in outflow graft
near valve
1
Noted at explantation
Hole in outflow
graft near valve
2 1 4
Hole in inflow graft
near valve
3
Hole in inflow valve 1
Mean duration to device
malfunction (days)
66.2 29.1 213.1 178.6 95.4 68.9
Median duration to
device malfunction
(days)
65.2 134.4 62.5
PNEUM, Pneumatic device; DLVE, Dual-lead vented electric device; SLVE,
single-lead vented electric device.
TABLE 4. Incidence of CVA and TIA while on LVAD support
Neurological
complication PNEUM DLVE SLVE P*
CVA 4 (7.7%)† 2 (11.8%) 7 (4.0%) .443
TIA 0 0 11 (6.3%) .223
CVA, Cerebrovascular accident (stroke); TIA, transient ischemic attack;
LVAD, left ventricular assist device; PNEUM, pneumatic device; DLVE,
dual-lead vented electric device; SLVE, single-lead vented electric device.
*P values from chi-square analysis.
†Absolute number (percentage of total).
TABLE 5. Univariate analysis of factors affecting success-
ful bridging to transplant
Variable P
Age .080
Gender .001
Race
Caucasian .751
African American .383
Other .407
Device type
PNEUM .571
DLVE .901
SLVE .763
Etiology of heart failure
CAD .044
ICM .003
Other .048
Duration of support .001
Device malfunction .412
Infection .111
Drive line .530
Pocket .095
Pump .557
LVAD score .001
PNEUM, Pneumatic device; DLVE, dual-lead vented electric device; SLVE,
single-lead vented electric device; CAD, coronary artery disease; ICM,
idiopathic cardiomyopathy; LVAD, left ventricular assist device.
TABLE 6. Factors affecting successful bridging to trans-
plant using multivariate, stepwise logistic regression
Variable OR 95% CI P SE
LVAD score 1.214 1.119-1.316 .001 0.041
OR, Odds ratio; CI, confidence interval; SE, standard error; LVAD, left
ventricular assist device.
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regimen consisting of cyclophosphamide and intravenous
immunoglobulin for all sensitized patients beginning in
1997. The use of this immunomodulatory therapy reduced
both the waiting time and risk of acute rejection in sensi-
tized recipients.27 Because of the increased frequency of
sensitization among Thoratec HeartMate LVAD recipients,
it is important that panel-reactive antibody testing be per-
formed at regular intervals. It has been suggested that sen-
sitized patients may be at risk for the development of
anti-human leukocyte antigen antibodies in the posttrans-
plant period, thereby potentially contributing to deleterious
effects on the cardiac allograft. Thus, these patients may
merit closer follow-up and more targeted immunosuppres-
sion.
The HeartMate Thoratec is the preferred device at our
institution for long-term support as a bridge to transplanta-
tion. Its advantages include portability and mobility, along
with lower cost of support by allowing patients to be dis-
charged from the hospital.28 Additionally, long-term anti-
coagulation is not required with the HeartMate, although it
is possible that with judicious use of postoperative antico-
agulation, the incidence of CVAs and TIAs may be de-
creased. This, however, requires further analysis in a ran-
domized trial. Design improvements that have contributed
to better device performance include transformation to a
single percutaneous lead, outflow graft bend relief, a smaller
and more flexible percutaneous cable, additional inflow
valve anchoring sutures, and the Opti-Fill software.3
The main limitations to the HeartMate device, however,
is that it is a univentricular support system and requires
cardiopulmonary bypass for insertion as inflow must origi-
nate from the left ventricular apex. Its application is also
limited in small-sized patients (body surface area  1.5 m2)
secondary to size requirements of the device, where other
devices may be considered.29,30
Limitations of this study include those related to a ret-
rospectively performed analysis. Clinical data were ob-
tained by chart review, which has inherent limitations, such
as access and accuracy of the data. Additionally, as a
retrospective observational study, it is subject to selection
bias and incomplete data collection. Finally, extrapolation
of the results regarding improved success in bridging pa-
tients to transplant and posttransplant survival with the
HeartMate is limited because of interinstitutional variability
in clinical practice.
In conclusion, although the paradigm for assist devices
may shift to a bridge to recovery or destination therapy, the
role of an LVAD as a bridge to transplantation for patients
with end-stage heart failure will remain an important
one.31-33 In reviewing our institutional experience, we noted
progressive improvements in bridging to transplantation
success and posttransplant survival. Improvements in these
outcome measures over the last 12 years occurred as a result
of improved patient selection as well as many major ad-
vances in preoperative, intraoperative, and postoperative
clinical practices. During this time period, there were also
temporal improvements in device design. Our challenge is
to continue to improve upon patient selection and periop-
erative management, as well to design smaller, infection-
resistant, more durable devices to make LVADs increas-
Figure 3. Bridging to transplant success based on preimplanta-
tion LVAD scores. LVAD scores were categorized as low (0-4),
medium (5-7), and high (8-10).
TABLE 7. Changes in clinical practice that have occurred
along with temporal changes in device design
Preoperative Intraoperative Postoperative
IABP Aprotinin Nitric oxide
Early LVAD
implantation
Bioglue Phosphodiesterase
inhibitors
(Milrinone)
Optimize fluid status Nitric oxide Aggressive use of
RVADs for RV
failure
Broad-spectrum
antibiotics
Phosphodiesterase
inhibitors (Milrinone)
Avoid excessive
blood products
Screening for PFO Early institution of
CVVH
Modification of outflow
tract anastomosis
Arginine
vasopressin
Vancomycin around
preperitoneal pocket
Improved ICU
care
IMT for sensitized
patients
IABP, Intra-aortic balloon pump; LVAD, left ventricular assist device; PFO,
patent foramen ovale; RVAD, right ventricular assist device; RV, right
ventricle; CVVH, continuous veno-venous hemofiltration; ICU, intensive
care unit; IMT, immunomodulatory therapy.
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ingly more effective in bridging patients with end-stage
heart failure to transplantation.
Dr Yoshifumi Naka, MD, PhD, is Herbert Irving Assistant
Professor of Surgery at Columbia University, College of Physi-
cians and Surgeons. Dr Vivek Rao, MD, PhD, is the Second
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